Market Place
Sourcing Support
Does Vaxart Hold The Key To The Elusive Norovirus Vaccine?
17 Feb 2026 //
BIOSPACE
Takeda consolidates Boston footprint
11 Feb 2026 //
FIERCE PHARMA
FDA Accepts Takeda`s Oveporexton NDA For Priority Review
10 Feb 2026 //
BUSINESSWIRE
Takeda Inks $1.7B AI Discovery Deal With Iambic Therapeutics
09 Feb 2026 //
FIERCE BIOTECH
Iambic Collaborates With Takeda On Ai-Driven Small Molecule
09 Feb 2026 //
BUSINESSWIRE
Takeda Looks To Put Generic Vyvanse Woes In The Rearview
30 Jan 2026 //
FIERCE PHARMA
Takeda Reports Third-Quarter FY2025 Results
29 Jan 2026 //
BUSINESSWIRE
Takeda Launches Low-IgA GAMMAGARD LIQUID in U.S
22 Jan 2026 //
BUSINESSWIRE
Takeda Slashes US Headcount, Hitting Neuro Commercial Teams Hard
19 Jan 2026 //
BIOSPACE
Protagonist`s $400M JPM26 Decision Is Total No-Brainer
16 Jan 2026 //
BIOSPACE
Takeda Leader Says AI Gave Early-Stage Asset A `Phoenix` Rebirth
13 Jan 2026 //
FIERCE BIOTECH
JPM26, Day 1: Updates From Lilly, Takeda, Novartis And Sofinnova
12 Jan 2026 //
FIERCE BIOTECH
Halozyme, Takeda Agreement To Develop Vedolizumab With ENHANZE
08 Jan 2026 //
PR NEWSWIRE
Takeda Shapes Future Clinical Research With Trial Representation
05 Jan 2026 //
BIOSPACE
Takeda, Protagonist Submit Rusfertide (NDA) For Polycythemia Vera
05 Jan 2026 //
BUSINESSWIRE
XOMA Royalty, Takeda Strike Mezagitamab Royalty Deal
30 Dec 2025 //
GLOBENEWSWIRE
Takeda`s AI-crafted Psoriasis Pill Succeeds in Late-Stage Studies
22 Dec 2025 //
REUTERS
Takeda Looks To 2026 FDA Filing For Sotyktu Rival Zasocitinib
18 Dec 2025 //
FIERCE BIOTECH
BaseLaunch Welcomes Takeda As Pharma Partner In Biotech Venture
16 Dec 2025 //
PR NEWSWIRE
Kamada Halts Phase 3 Inhaled AAT Trial, Retains 2025 Guidance
08 Dec 2025 //
GLOBENEWSWIRE
Merck mulls PV program’s future while Takeda takes victory lap
08 Dec 2025 //
FIERCE BIOTECH
Protagonist, Takeda Present Rusfertide PV Data at ASH 2025
06 Dec 2025 //
BUSINESSWIRE
Takeda Seals $1.2 Billion Oncology Deal With Innovent Biologics
04 Dec 2025 //
PRESS RELEASE
Takeda`s Adzynma draws FDA scrutiny after paediatric death
21 Nov 2025 //
FDA
Beacon Biosignals Expands Collaboration With Takeda
19 Nov 2025 //
GLOBENEWSWIRE
Neurocrine-Takeda Psychiatry Pact Suffers Another Phase 2 Fail
11 Nov 2025 //
FIERCE BIOTECH
Takeda Reveals Mezagitamab TAK-079 Maintains Kidney Function
07 Nov 2025 //
BUSINESSWIRE
Ph 3 Data Show Takeda Dengue Vaccine Gives 7 Years Protection
03 Nov 2025 //
BUSINESSWIRE
Takeda Maintains FY2025 Plan Despite FX Impact And Pipeline
30 Oct 2025 //
BUSINESSWIRE
Takeda Drops Az-Partnered Neurological Program After Ph. 2 Fail
30 Oct 2025 //
FIERCE BIOTECH
HyHub and HyHub Duo Launch in U.S. for Easier HYQVIA Prep
27 Oct 2025 //
BUSINESSWIRE
China`s Innovent Signs $11.4 B Cancer Therapy Deal with Takeda
22 Oct 2025 //
REUTERS
Nanoform Study Results To Be Presented At 2025 PODD Summit
21 Oct 2025 //
PHARMIWEB
Nabla Bio, Japan`s Takeda Expand AI Drug Design Partnership
14 Oct 2025 //
REUTERS
Takeda Exits Cell Therapy Research
05 Oct 2025 //
INDPHARMAPOST
Takeda Exits Cell Therapy, Dealing Blow To Promising Modality
02 Oct 2025 //
BIOSPACE
Bms, Takeda Join Peers In Push To Improve AI By Pooling Data
01 Oct 2025 //
FIERCE BIOTECH
Takeda Ends All Cell Therapy Work As Part Of Strategic Shift
01 Oct 2025 //
FIERCE BIOTECH
Takeda Plasma-Derived Therapies Team Conquers Mount Fuji
19 Sep 2025 //
FIERCE PHARMA
Takeda, VELA to Ship Meds Via First Wind-Powered Trimaran
16 Sep 2025 //
PHARMAWEB
Takeda to Ship Products Between Europe and U.S. via Cargo Vessels
16 Sep 2025 //
PRESS RELEASE
Nanoform Study Results to be Unveiled at US DDF Summit
11 Sep 2025 //
PHARMAWEB
Takeda Names Rhonda Pacheco as U.S. Business Unit President
11 Sep 2025 //
CONTRACTPHARMA
CVS Sues Takeda Over `Pay-For-Delay` Scheme
10 Sep 2025 //
FIERCE PHARMA
Takeda Reveals Ph3 Orexin Data for Narcolepsy at World Sleep 2025
08 Sep 2025 //
PHARMAWEB
Takeda, Alkermes Reveal Narcolepsy Rivals Amid Intensifying Race
08 Sep 2025 //
FIERCE BIOTECH
FDA Expansion Approves of Vonvendi for Von Willebrand Disease
06 Sep 2025 //
BUSINESSWIRE
Takeda Reports Q1 FY2025 Results, Late-Stage Pipeline Progress
30 Jul 2025 //
BUSINESSWIRE
Takeda Revenue Drops Due to Vyvanse Sales Issues
30 Jul 2025 //
FIERCE PHARMA
Takeda Gets FDA Clearance for HyHub™ Devices
21 Jul 2025 //
BUSINESSWIRE
Chasing Takeda, Alkermes Reports Phase 2 Narcolepsy Win
21 Jul 2025 //
FIERCE BIOTECH
Keros Therapeutics Doses First Patient in Phase 3 RENEW trial
18 Jul 2025 //
GLOBENEWSWIRE
Takeda Establishes Lead in Narcolepsy Race With 2 Phase 3 Win
15 Jul 2025 //
BIOSPACE
Takeda`s Gammagard Liquid ERC Approved by U.S. Fda
30 Jun 2025 //
BUSINESSWIRE
Takeda Announces New Assignments of Directors
25 Jun 2025 //
BUSINESSWIRE
EC Approves Adcetris for Treating Adult Hodgkin Lymphoma
03 Jun 2025 //
BUSINESSWIRE
Protagonist & Takeda`s ASCO Presentation on Ph 3 VERIFY Study
01 Jun 2025 //
BUSINESSWIRE
Takeda and Nature Call for Applications for 2026 Award
27 May 2025 //
BUSINESSWIRE
NEJM Publishes TAK-861 Phase 2b Narcolepsy Type 1 Trial Data
14 May 2025 //
BUSINESSWIRE
Takeda eyes upcoming launches as Vyvanse generics hit lingers
09 May 2025 //
FIERCE PHARMA
